Selective EP4 Receptor Antagonism for Osteoarthritis Pain: Emerging Evidence and Future Directions for KF-0210

Osteoarthritis (OA) is a leading cause of chronic pain and disability. Its increasing global prevalence and substantial socioeconomic burden highlights need for safer and more effective therapeutic strategies. Current pharmacological treatments provide symptomatic relief; however, are limited by gastrointestinal, cardiovascular, renal, and other adverse effects. Prostaglandin E2 (PGE2)-mediated EP4 receptor signaling plays a central role in OA pain, peripheral sensitization, subchondral bone remodeling, and cartilage degeneration, which makes EP4 an attractive therapeutic target. Current evidence suggests that KF-0210 is a potential therapy for OA pain and the present investigation summarizes pathophysiology of OA pain, the biological role of PGE2–EP4 signaling pathway, and the rationale for selective EP4 antagonism as a targeted alternative to conventional cyclooxygenase inhibition. Preclinical and clinical evidence for the oral EP4 antagonist KF-0210 is reviewed, including pharmacological properties, analgesic efficacy, safety profile, and potential disease-modifying mechanisms compared with existing OA therapies. Although the available evidence remains preliminary, selective EP4 antagonism represents a novel therapeutic strategy that requires further investigation.